Nubeqa plus ADT improved HRQoL and delayed pain progression in mHSPC patients, outperforming placebo plus ADT. The FDA approved Nubeqa for mHSPC based on ARANOTE trial data, highlighting its clinical ...
Nubeqa with androgen deprivation therapy reduces radiological progression risk by 46% and death risk by 19% in metastatic hormone-sensitive prostate cancer. Nurses are essential in educating patients ...
Feb 10 (Reuters) - Finnish drug manufacturer Orion (ORNBV.HE), opens new tab posted a smaller-than-expected rise in fourth-quarter profit on Thursday as robust sales of its prostate cancer drug Nubeqa ...
MedPage Today on MSN
Similar prostate cancer drugs show different results in real-world study
Better short-term survival with apalutamide versus darolutamide, but lots of unanswered qu ...
Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results